Literature DB >> 3263879

Effect of recombinant and purified human haematopoietic growth factors on in vitro colony formation by enriched populations of human megakaryocyte progenitor cells.

L Lu1, R A Briddell, C D Graham, J E Brandt, E Bruno, R Hoffman.   

Abstract

Nonadherent low density T-lymphocyte depleted (NALT-) marrow cells from normal donors were sorted on a Coulter Epics 753 Dye Laser System using Texas Red labelled My10 and phycoerythrin conjugated anti HLA-DR monoclonal antibodies in order to obtain enriched populations of colony forming unit-megakaryocyte (CFU-MK). The CFU-MK cloning efficiency (CE) was 1.1 +/- 0.5% for cells expressing both high densities of My10 and low densities of HLA-DR (My10 DR+). This procedure resulted in an 18-fold increase in CE over NALT- cells. The effect of purified or recombinant human haematopoietic growth factors including erythropoietin (Epo), thrombocytopoiesis stimulating factor (TSF), interleukin 1 alpha (IL-1 alpha), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF or CSF-1) and interleukin MK colony formation by My10 DR+ cells was determined utilizing a serum depleted assay system. Neither Epo, TSF, CSF-1, IL-1 alpha nor G-CSF alone augmented MK colony formation above baseline (2.5 +/- 0.8/5 x 10(3) My10 DR+ cells plated). In contrast, the addition of GM-CSF and IL-3 each increased both CFU-MK colony formation and the size of colonies with maximal stimulation occurring following the addition of 200 units/ml of IL-3 and 25 units/ml of GM-CSF. At maximal concentration, IL-3 had a greater ability to promote megakaryocyte colony formation than GM-CSF. The stimulatory effects of GM-CSF and IL-3 were also additive in that the effects of a combination of the two factors approximated the sum of colony formation in the presence of each factor alone. The CFU-MK appears, therefore, to express HPCA-1 and HLA-DR antigens. These studies also indicate that GM-CSF and IL-3 are important in vitro regulators of megakaryocytopoiesis, and that these growth factors are not dependent on the presence of large numbers of macrophages or T cells for their activity since the My10 DR+ cells are largely devoid of these accessory cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263879     DOI: 10.1111/j.1365-2141.1988.tb02456.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Analysis of CD34-positive hemopoietic progenitor cells from normal human adult peripheral blood: flow-cytometrical studies and in-vitro colony (CFU-GM, BFU-E) assays.

Authors:  S Serke; S Säuberlich; Y Abe; D Huhn
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

2.  Regulation of megakaryocyte phenotype in human erythroleukemia cells.

Authors:  M W Long; C H Heffner; J L Williams; C Peters; E V Prochownik
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

3.  Macrophages prevent human red blood cell reconstitution in immunodeficient mice.

Authors:  Zheng Hu; Nico Van Rooijen; Yong-Guang Yang
Journal:  Blood       Date:  2011-09-16       Impact factor: 22.113

4.  Megaloblastic hematopoiesis in vitro. Interaction of anti-folate receptor antibodies with hematopoietic progenitor cells leads to a proliferative response independent of megaloblastic changes.

Authors:  A C Antony; R A Briddell; J E Brandt; J E Straneva; R S Verma; M E Miller; L A Kalasinski; R Hoffman
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

5.  Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.

Authors:  G J Veldhuis; P H Willemse; J H Beijnen; H Boonstra; H Piersma; W T van der Graaf; E G de Vries
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

Authors:  M W Dercksen; K Hoekman; W W ten Bokkel Huinink; E M Rankin; R Dubbelman; H van Tinteren; J Wagstaff; H M Pinedo
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.